<?xml version="1.0" encoding="UTF-8"?><mods xmlns="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" version="3.2" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd"><titleInfo><title>Enzymes involved in the conversion of arachidonic acid to eicosanoids in the skin of atopic dogs</title></titleInfo><name><namePart>Schlotter, Y.M.</namePart></name><name><namePart>Riemers, F.M.</namePart></name><name><namePart>Rutten, V.P.M.G.</namePart></name><name><namePart>Knol, E.F.</namePart></name><name><namePart>Willemse, T.</namePart></name><subject lang="nl"><topic>atopic dermatitis</topic><topic>arachidonic acid</topic><topic>cyclooxygenase pathway</topic><topic>dogs</topic><topic>lipoxygenase pathway</topic></subject><accessCondition></accessCondition><location><url>http://igitur-archive.library.uu.nl/vet/2010-1026-200247/UUindex.html</url></location><language><languageTerm type="text">en</languageTerm></language><genre authority="local">journalArticle</genre><originInfo><publisher>Wiley</publisher><dateIssued>2010</dateIssued></originInfo><identifier type="issn">0906-6705</identifier><abstract>Canineatopic dermatitis (AD), a chronic inflammatory
skin disease, shares characteristics with its human counterpart.
To get insight into the role of enzymes involved in production of
prostaglandin E2 (PGE2) and leukotriene B4 (LTB4), potent
inflammatory mediators originating from membrane-derived
arachidonic acid (AA), expression of genes encoding these
enzymes and receptors was quantified by qPCR in non-lesional
and lesional skin from atopic dogs and in healthy skin.
Significantly higher mRNA expression of the key enzymes
5-lipoxygenase (5-LO), 5-LO activating protein (FLAP),
leukotriene A4 hydrolase (LTA4H) and prostaglandin E synthase 1
(mPGES-1) and their receptors (PGE receptors 2 and 3) were
observed. Being responsible for elevated levels of metabolites of
the 3-series prostaglandins and the 5-series leukotrienes these
enzymes may be interesting targets for therapy that should result
in amelioration of clinical signs in canine atopic dermatitis</abstract><relatedItem type="host"><titleInfo><title>Experimental Dermatology</title></titleInfo><publisher>Wiley</publisher>
<originInfo><dateIssued>2010</dateIssued>
</originInfo><identifier type="issn">0906-6705</identifier>
<identifier type="doi">URN:NBN:NL:UI:10-1874-187037</identifier>
<part><detail type="volume"><number>19</number></detail>
<extent unit="page"><start>e317</start>
<end>e319</end>
</extent></part></relatedItem></mods>
